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Abstract
Background: Tauopathy is characterized by neurofibrillary tangles composed of insoluble hyperphosphorylated tau
protein. Currently, cellular models that mimic neurofibrillary tangles in vitro are lacking. Previous studies indicate
that neurofibrillary tangles form via a prion replication mechanism. In the present work, we establish a seeding
based cellular model according to the prion hypothesis.
Results: We show that cellular soluble tau can be converted to insoluble tau by seeds from the brain lysate of
rTg4510 mice or synthetically generated preformed tau fibrils (PFFs). The cellular insoluble tau exhibits classic
features of neurofibrillary tangles. Using genetic and pharmacological methods, we demonstrate that inhibition
of autophagy increases whereas enhancement of autophagy reduces insoluble tau in our seeding based cellular
model. The insoluble tau can be detected and quantified by thioflavin-S staining, thus allowing us to adapt our
cellular model to a high-content image-based screening platform.
Conclusions: Our seeding based cellular model reproduces neurofibrillary tangle pathology in vitro and serves as a
useful tool for studying tauopathy and identifying tau modulators.
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Background
Tauopathy is a group of neurodegenerative diseases
characterized by the accumulation of neurofibrillary tan-
gles (NFTs) composed of tau protein aggregates within
the neurons [1]. The most well-known tauopathy is
Alzheimer’s disease in which NFTs develop and progress
along defined network connections and form the basis
for the widely accepted pathologic staging of AD, the
Braak Staging [2]. Compelling evidence supports the
notion that neurofibrillary tangle pathology causes
neurodegeneration in and of itself [3, 4]. Besides AD,
NFTs are observed in other tauopathies as well, such
as frontotemporal dementia, progressive supranuclear
palsy, and Pick’s disease among others [1]. Recently,
Huntington’s disease has also been described as a type
of tauopathy [5–7].
In physiological conditions, tau protein is unstructured
and associates with microtubules in neuronal axons.
However, under pathological conditions, tau protein is
hyperphosphorylated, which leads to its dissociation
from the microtubules and formation of paired helical
filaments, referred to as neurofibrillary tangles, in cell
bodies and dendrites [1]. Due to its strong hydrophilic
nature, the tau protein typically does not form a well-
ordered fibrilar structure in vitro. Two methods have
been used to produce tau fibrils. One is through charge
compensation by polyanions to form tau filaments from
recombinant tau protein. The other is through cellular
expression of truncated tau that displays high amyloido-
genic potential [3]. Different truncations of tau have
been used by different laboratories to overcome the lack
of amyloidogenic propensity and cytotoxicity of the full
length tau. The repeat domain (RD) of tau that binds to
microtubules makes up the most commonly used ver-
sion of truncated tau [8]. Besides the RD, C-terminal
truncated tau has been shown to be degraded through
the autophagy lysosomal degradation pathway [5], N-
terminal truncated tau changes the ability to bind and
stabilize microtubules [9], and the calpain-cleaved 17kD
tau fragment exhibits prominent neuronal toxicity [10,
11]. Although these cellular models are useful to study
tau aggregation, there are a number of disadvantages.
First, it is rare to produce insoluble tau in these cells
even using truncated tau. Among those models,
thioflavin-S positive staining is only observed in tau RD
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Δ280 cell models and the efficiency is very low (about
6 % of cells are thioflavin-S positive) [12]. Second, trun-
cations of tau may change the intrinsic features of full
length tau. Third, there is still no solid evidence to sup-
port the existence of truncated tau in animal models or
in human brains. Last, truncated tau may induce strong
cytotoxicity, which makes maintaining a stable cell line
difficult [13]. The aforementioned concerns could vastly
explain the difficulties in translating results from current
truncated tau cellular models to animal studies.
Although the precise mechanism of neurofibrillary
tangle formation is not fully understood, several studies
have implicated that it is likely subject to prion-like
pathogenesis [13, 14]. The prion protein can exist in
different conformations. Under the pathological con-
formation, monomeric prion protein can form small
oligomeric seeds at a very slow rate. After seed forma-
tion, monomeric prion protein attaches to the two ter-
minal ends of the seed and forms amyloid filaments at a
much faster rate [15, 16]. This hypothesis could explain
the challenges in forming NFTs in cells as compared to
mouse models. Since cellular models can only be main-
tained for a matter of days or weeks, it may not be suffi-
cient to allow seed formation. In contrast, the NFTs
pathology can develop over a long period of time in
mouse or human brains. Here, we seek to establish a cel-
lular assay of neurofibrillary tangles using full length tau
to avoid the shortcomings of the truncated tau. Building
on the prion hypothesis, we used brain lysate from
rTg4510 mice or PFFs as seeds to bypass the seed forma-
tion step in cells. As a result, we successfully accelerated
cellular NFTs formation and established a seeding based
cell assay. Furthermore, we validated this assay by ma-
nipulating the autophagy-lysosomal pathway molecules.
Finally, using thioflavin S staining as a detection method,
we adapted this assay to a high-content capacity to allow
screening of insoluble tau modulators.
Results and discussion
Establishment of a seeding based cell assay for tauopathy
Recent studies have shown that pathological tau exhibits
prion-like replication and spreading phenomenon in-
duced by seeding [13, 14]. Therefore, we designed a
seeding based cellular tauopathy model (Fig. 1a and de-
scribed in detail in Methods). Because prion amyloid
amplification occurs in a sequence-dependent manner,
brain lysate from aged rTg4510 tau transgenic mice was
used as seeds and added into the culture medium of
HEK293 cells expressing vector or tau-PL-V5 containing
the same tau sequence (Fig. 1b). In HEK293 cells trans-
fected with the pCMV control plasmid, treatment with
brain lysate from control (Ctrl lysate) or tau transgenic
(Tg lysate) mice failed to induce insoluble tau (Fig. 1b).
This is also the case when control brain lysate (Ctrl
lysate) was applied to cells transfected with tau-PL-V5
plasmid (Tau-PL-V5). In contrast, insoluble tau was in-
duced only in tau-PL-V5 transfected cells treated with
brain lysate from rTg4510 transgenic mice (Fig. 1b, Tg lys-
ate +; Tau-PL-V5 +). Insoluble tau was V5 positive, dem-
onstrating that it is converted from cellular soluble tau,
not from residual brain lysate. Taking into consideration
that the intensity of insoluble PHF1 bands is about half of
the soluble PHF1 (Fig. 1b) and that approximately 5-fold
more insoluble proteins than soluble proteins were loaded,
we estimated that the conversion rate is roughly 1/10 (in-
soluble/soluble), consistent with low conversion efficiency
reported in previous studies [17]. It is known that patho-
logical tau accumulates with aging in the brain of rTg4510
mice. To further confirm that insoluble tau is induced by
seeding, we used brain lysate from different ages of the
mice as seeds (Fig. 1c). As expected, the amount of insol-
uble tau (both PHF1 and V5 positive) was increased in
cells treated with older Tg brain lysate compared to cells
treated with younger lysate, suggesting that the seeding
activity of Tg brain lysate increases in an age dependent
manner. Besides the brain lysate, synthetic tau fibrils have
also been used as seeds to induce tau pathology [13, 14].
We thus used PFFs prepared from recombinant synthetic
K18-PL that contains the microtubule-binding domain of
tau with the same P301L mutation as seeds. As shown in
Fig. 1d, K18-PL PFF also induced insoluble tau in tau-PL-
V5 transfected cells similar to the brain lysate. In our
study, neither the rTg4510 brain lysates nor K18-PL PFF
was able to convert the wild type tau to insoluble form
(data not shown). Further, application of the same amount
of insoluble seeds as that of rTg4510 from another tau
transgenic mice, PS19, which expresses the P301S instead
of P301L mutation, failed to convert the tau-PL-V5 to in-
soluble form at any appreciable levels (Fig. 1e, compare
rTg4510 vs. PS19, Insoluble vs. Soluble), suggesting that
either the conversion requires the same host-agent se-
quence or that the conversion efficiency induced by differ-
ent mutations is too low to be detected in our assay.
Characterization of seeding induced tau pathology
To further characterize seeding induced tau pathology,
control vector (pCMV) or tau-PL-V5 (Tau-PL) trans-
fected cells seeded lysates from control (Ctrl lysate) or
rTg4510 (Tg lysate) brains were stained with the PHF1
antibody after 1 % Triton X-100 wash to remove the sol-
uble tau (Fig. 2a). Consistent with the biochemical re-
sults, vector transfected cells seeded with Tg lysate
(pCMV + Tg lysate) or tau-PL-V5 transfected cells
seeded with control lysate (Tau-PL + Ctrl lysate) did not
result in detectable PHF1-positive fluorescence. How-
ever, 15–20 % of the Tau-PL transfected cells seeded
with Tg lysate displayed PHF1-positive staining (Fig. 2a,
Tau-PL + Tg lysate). Insoluble tau in cells exhibited
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Fig. 1 Establishment of seeding based cell assay for tauopathy. a Experimental scheme for the seeding based cellular assay. Brain lysate from
rTg4510 mice or PFFs were added into the medium of HEK293 cells expressing Tau-PL-V5 (1:1000 dilution for brain lysate and 1:250 dilution for
PFF). After 1 day incubation, cell lysate was subjected to ultracentrifugation to isolate soluble and insoluble protein pool. b Cells were transfected
with Tau-PL-V5 plasmid. pCMV5 plasmid was used as control. The transfected cells were then treated with Tg or control brain lysates. Western
blots show that cellular insoluble tau could only be induced in cells expressing Tau-PL-V5 and treated with Tg brain lysate, but not in other
groups. c Cells were transfected with Tau-PL-V5 plasmid. pCMV5 plasmid was used as control. Transfected cells were treated with equal amount
of the brain lysates from 1, 4 and 7 month old Tg mice. Western blots show that seeding activity of brain lysate increased in an age dependent
manner. d Cells were transfected with Tau-PL-V5 plasmid. pCMV5 plasmid was used as control. The transfected cells were treated with PFF or
PBS. Western blots show that PFFs also could be used as seeds to trigger insoluble tau in seeding based cellular assay. e Cells were transfected
with Tau-PL-V5 plasmid. The transfected cells were treated with control, 4 month rTg4510 or 9 month PS19 brain lysates. Western blots show that
only rTg4510 brain lysate could trigger insoluble tau in seeding based cellular assay
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Fig. 2 Characterization of seeding induced tau. a Soluble proteins were extracted by 1 % Triton X-100 during fixation. Representative images
show that insoluble tau is recognized by phosphorylated tau antibody PHF1 in cells expressing Tau-PL-V5 and treated with Tg brain lysate, but
not in other groups. The higher magnification views were shown in the bottom panel. b Representative images show that insoluble tau is
thioflavin-S, total-tau, and V5 positive. The enlarged views were shown in the bottom panel. Scale bars: 100 μm
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cytosolic localization (see Fig. 2a, PHF1 and DAPI
Merge). The tau species were also thioflavin-S positive
(Fig. 2b), suggesting that seeding induced insoluble tau
resembles the neurofibrillary tangles in vivo. Thioflavin-
S, total-tau, and V5 staining were almost entirely over-
lapping, demonstrating that the insoluble tau was
converted from cellular soluble tau. Based on the bio-
chemical and immunofluorescent results, we conclude
that extracellular seeding can induce intracellular soluble
tau to convert to an insoluble and aggregated form rem-
iniscent to the pathological hallmarks of neurofibrillary
tangles in aged tauopathy mouse models and human
patients.
Genetic and pharmacological validation of seeding based
cell assay
Autophagy is a conserved cellular clearance mechanism,
which has been widely reported to degrade pathological
tau in vivo [18, 19]. To validate that our seeding based
cell assay can simulate the in vivo conditions and is
compatible with its regulatory mechanisms, different
methods were used to manipulate autophagy in the
seeding based cell assay (Fig. 3). Trehalose is a well-
documented autophagy activator [20]. In vivo study has
demonstrated that trehalose treatment specifically re-
duces insoluble tau and reverses neurodegeneration
[19]. Indeed, trehalose treatment led to dose-
dependent increase of soluble and total LC3-II levels
(Fig. 3a, LC3 lower band) and corresponding reduc-
tion in the insoluble tau (Fig. 3a, Insoluble PHF1 and
V5). This was further confirmed by quantification of
insoluble V5 tau levels (Fig. 3b). On the contrary,
treatment with bafilomycin A1, an autophagy and
lysosomal degradation inhibitor, significantly increased
p62, a protein marker for autophagic flux (Fig. 3c)
[21]. As expected, inhibition of autophagy and lyso-
somal degradation led to a significant increase in the
accumulation of insoluble PHF1 and V5-positive tau
(Fig. 3c and quantified in 3d).
We reported previously that transcription factor EB
(TFEB), a master regulator of the autophagy and lyso-
somal pathway, and its downstream target phosphatase
and tensin homolog (PTEN), can induce robust tau
degradation [22]. Here, we validated that overexpression
of TFEB (Fig. 3e and quantified in 3f) and PTEN (Fig. 3g,
h) significantly decreased both insoluble and soluble tau
in our seeding based assay. Next, we blocked autophagy
using siRNA targeting of autophagy-related genes
Beclin1 (Fig. 3i, j) and Atg5 (Fig. 3k, l) [23, 24]. Our re-
sults showed that both Beclin1 and Atg5 were downreg-
ulated by si-RNA knockdown (Soluble and Total, Fig. 3i,
si-Ctrl vs. si-Beclin1; Fig. 3k, si-Ctrl vs. si-Atg5). Under
these autophagy blockage conditions, insoluble tau was
increased as expected (Fig. 3i and k, insoluble PHF1 and
V5, with V5 quantified in Figs. 3j and l). This data
demonstrate that the seeding based assay is compatible
with the three types of most commonly used experimen-
tal manipulations: small molecule-based treatment,
plasmid mediated gene overexpression, and si-RNA
mediated gene knockdown, providing further support
for the utility of our seeding based assay for studies of
tauopathy.
Establishment of an image based screening platform
Without a useful cellular model, potential target genes
or drugs could only be identified and validated through
time and labor intensive animal experiments in tauopa-
thy studies. Here, we retrofitted our seeding based cellu-
lar assay to a high content screening modality (Fig. 4a
and described in details in Methods). We plated the
HEK293 cells expressing the vector or tau-PL-V5 into
96-well plates. After seeding with control or Tg lysate or
tau PFF, thioflavin-S staining was performed to deter-
mine the amount of cytosolic insoluble tau species. As
previously demonstrated, the thioflavin-S positive signal
was only detected in cells expressing tau-PL-V5 and
treated with Tg lysate (Tau-PL-V5, Tg lysate, Fig. 4b with
quantification in 4d) or tau PFF (Tau-PL-V5, PFF, Fig. 4c
and quantified in 4e), but not in control lysate treated or
vector expressing cells.
Validation of image based screening platform
To further validate our screening platform, we tested the
fluorescence intensity of thioflavin-S staining under
various treatment conditions. Consistent with the bio-
chemical results, trehalose (Tre) or bafilomycin A1 (Baf )
treatment led to reduced and increased thioflavin-S
signal respectively (Fig. 5a and quantified in Fig. 5b).
Overexpression of TFEB or PTEN induced significant
reduction of fluorescence intensity (Fig. 5c and quanti-
fied in 5d). Blockage of autophagy through si-RNA
meditated knockdown of Beclin1 or Atg5 resulted in
increased fluorescence intensity (Fig. 5e and quantified
in Fig. 5f ). These data demonstrate that our seeding
based cell assay is compatible with different experimen-
tal conditions and could be used as a screening system.
Autophagy deficit has been implicated in several neuro-
degenerative diseases including tauopathy. Manipulation
of this pathway is considered a potential therapeutic
approach for these conditions. Here we validated several
autophagy related molecules in our seeding based cell
model, including key transcriptional and post-translational
regulators of autophagy and small molecule autophagy
modulators. Thus this screening system can be used to
discover novel pathways or small molecule tau/NFTs
modulators for mechanistic studies and therapeutic
targeting respectively.
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Fig. 3 (See legend on next page.)
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Fig. 4 Establishment of image based screening platform. a Experimental scheme for the image based screening platform. Seeding
assay was performed in 96-well plate and subjected to thioflavin-S staining. Images were captured by EVOS fluorescent microscopy.
b Representative images show thioflavin-S positive signal only in cells expressing Tau-PL-V5 and treated with Tg brain lysate, but not
in other groups. c Representative images show thioflavin-S positive staining signal only in cells expressing Tau-PL-V5 and treated with
PFFs, but not in other groups. d Quantitative analyses of (b). e Quantitative analyses of (c). Graphical data are expressed as mean ±
SEM (***P < 0.001, t-test). Scale bars: 100 μm
(See figure on previous page.)
Fig. 3 Validation of seeding based cell assay under different conditions. a Western blots show decreased insoluble tau in cells treated with
different concentrations of trehalose. b Quantitative analyses of (a). c Western blots show increased insoluble tau in cells treated with different
concentrations of bafilomycin A1. d Quantitative analyses of (c). e Western blots show decreased insoluble tau in cells transfected with TFEB
overexpression plasmid. f Quantitative analyses of (e). g Western blots show decreased insoluble tau in cells transfected with PTEN
overexpression plasmid. h Quantitative analyses of (g). i Western blots show increased insoluble tau in cells transfected with Beclin1 siRNA.
j Quantitative analyses of (i). k Western blots show increased insoluble tau in cells transfected with Atg5 siRNA. l Quantitative analyses of
(k). Graphical data are expressed as mean ± SEM (***P < 0.001, **P < 0.01, *P < 0.05, t-test)
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Conclusion
In this study, we describe a seeding based cellular model
of tauopathy based on the prion hypothesis. We demon-
strate that extracellular seeding induces the conversion of
cellular soluble tau to insoluble thioflavin-S positive tau
resembling the classic hallmarks of neurofibrillary tangles
in tauopathy mice and human patients. The seeds may be
derived from different origins, either aged tauopathy
mouse brain lysate or synthetic tau fibers, which allows
for flexibility in the application of this assay. We manipu-
lated autophagy via three different techniques: small
molecule-based treatment, gene overexpression, and gene
knockdown, and validated that upregulation of autophagy
decreased insoluble tau, while downregulation of autoph-
agy increased insoluble tau. Thus this assay can be used
for investigating tau pathology in vitro. Further, we used
thioflavin-S fluorescence to visualize insoluble tau, making
the assay compatible with high-content image based
screening. In conclusion, our seeding based cellular assay
can be easily performed, are subject to various experimen-
tal manipulations, and the results are consistent and
quantifiable. This assay may be used in pre-validation ex-
periments prior to commencing animal studies of candi-
date genes or drugs and also offer a possible platform for
discovery studies and chemical screening of tauopathy.
Methods
Animals
The rTg4510 tau transgenic mice was obtained from the
Jackson laboratory and produced by crossing the trans-
activator line CaMKIIα (129S6 background) with the tau
responder line (FVB background) [25]. The wild-type lit-
termates were used as controls. All protocols involving
mice were approved by the Institutional Animal Care
and Use Committee of Baylor College of Medicine.
Seeds preparation
For brain lysate, forebrain tissues were lysed in 10 %
weight/volume in RIPA buffer (TBS with 1 % Triton X-
100, 0.1 % sodium dodecylsulfate and protease phosphat-
ase inhibitor cocktails). Cell lysate was sonicated for ten
pulses at output 5, 50 % duty cycle and centrifuged at
12,000 rpm for 15 min. Supernatants were aliquoted and
stored in − 80 °C until use. Recombinant tau was purified
and fibrillized in vitro to generate PFF as described pre-
viously [26]. Briefly, truncated tau containing only four
MT-binding repeats (4R) with a Myc tag at the 5’ end
and the P301L mutation (5’Myc-K18/P301L) were
cloned into NdeI/EcoRI sites in pRK172 bacterial ex-
pression vector (generous gift from Virginia Lee). The
protein was expressed in BL21 (DE3) RIL cells and
Fig. 5 Validation of image based screening platform. a Representative images show decreased thioflavin-S signal in cells treated with trehalose
and increased thioflavin-S signal in cells treated with bafilomycin A1. b Quantitative analyses of (a). c Representative images show decreased
thioflavin-S signal in cells overexpressing TFEB or PTEN. d Quantitative analyses of (c). e Representative images show increased thioflavin-S signal
in cells with knockdown of Beclin1 or Atg5. f Quantitative analyses of (e). Graphical data are expressed as mean ± SEM (***P < 0.001, **P < 0.01,
*P < 0.05, t-test). Scale bars: 100 μm
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purified by cationic exchange using a fast protein liquid
chromatography (FPLC). The purified protein under-
went in vitro fibrillization by mixing 40 μM recombinant
tau with 40 μM heparin and 2 mM DTT in 100 mM so-
dium acetate buffer (pH 7.0). The protein was then incu-
bated 2–3 days at 37 °C without agitation. Fibrillization
was confirmed using the thioflavin T fluorescence assay,
sedimentation test, and cryo electron microscopy. Prior
to use or storage, the fibrillization mixture was centri-
fuged at 100,000 × g for 30 min at 4 °C. The resulting
pellet was resuspended in 100 mM sodium acetate buffer
(pH 7.0), without heparin and DTT, to make a 40 μM
solution. The PFFs were then frozen as single use ali-
quots at − 80 °C. Prior to use in experiments, frozen ali-
quots were thawed followed by sonication of 30 brief
pulses.
Cell culture, transfection and seeding assay
HEK293 cells were maintained in DMEM (Life Technolo-
gies) with 10 % FBS at 37 °C with 5 % CO2. Cells were cul-
tured in 60 mm2 dish with 5 mL medium. Transfection
was performed based on manufacture’s protocol. Tau
P301L-V5 was a gift from Dr. Leonard Petrucelli (Mayo
Clinic, Jacksonville, Florida, USA), encoding full length
human tau with P301L mutation and V5 tag
(GKPIPNPLLGLDST). In brief, 2–4 μg tau P301L or
pCMV plasmids were diluted with Opti-MEM, then
added to lipofectamine 3000 regent and P3000 re-
agent. After 10–15 mins incubation, DNA-lipid com-
plex was added to medium. One day after transfection,
5 μL brain lysate or 20 μL PFF was added into culture
medium. One day after seeding, cells were collected in
ice-cold TBS.
Protein fractionation and western blotting
In one 60 mm2 dish, cells were lysed in 1 mL TBS with
1 % Triton X-100 and protease phosphatase inhibitor
cocktails. Then the lysate was sonicated with ten pulses
at output 4, 50 % duty cycle. 20 μL of supernatant was
collected as total protein fraction. The rest was subjected
to ultracentrifugation at 100,000 x g for 30 min. The
950 μL supernatant was collected as the Triton X-100
soluble fraction. Pellets were washed by 1 mL TBS with
1 % Triton X-100 and subjected to ultracentrifugation at
100,000 x g for 30 min again. Pellets from the second
ultracentrifugation step were resuspended in 200 μL TBS
with 1 % SDS and sonicated with 5 pulses at output 5,
50 % duty cycle, which 200 μL protein buffer was labeled
as the Triton X-100 insoluble fraction. All three fractions
were boiled in 5XSDS-sample loading buffer. 20 μL of
each fraction was loaded per gel for SDS-PAGE followed
by western blot.
Immunofluorescence assay
For immunostaining of insoluble tau, cells grown on
cover slips were fixed with 4 % paraformaldehyde and
1 % Triton X-100 at room temperature for 15 min. Cells
were incubated overnight with primary antibodies in
TBS blocking solution containing 0.4 % Triton X-100.
After washing, cells were incubated for 2 h with second-
ary antibody. For thioflavin-S staining, cells were incu-
bated with 0.002 % thioflavin-S in TBS, followed by
rinsing with 50 % EtOH twice, then 5 min in TBS before
imaging. Images were captured by EVOS fluorescent
microscopy.
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